Skip to content
10-K

Annual Report

BRAINSTORM CELL THERAPEUTICS INC. BCLI

0001104659-26-037927

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 27, 2026 11.03M sh
Shares Diluted FY 2025 · Dec 31, 2025 9.27M sh
Shares Diluted FY 2025 · Dec 31, 2024 5.02M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$6.98M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$9.09M
Short Term Debt FY 2025 · Dec 31, 2025 $967K
Short Term Debt FY 2025 · Dec 31, 2024 $300K
Cash And Equivalents FY 2025 · Dec 31, 2025 $29K
Cash And Equivalents FY 2025 · Dec 31, 2024 $187K
Stockholders Equity FY 2025 · Dec 31, 2025 −$9.99M
Stockholders Equity FY 2025 · Dec 31, 2024 −$7.76M
Stockholders Equity FY 2025 · Dec 31, 2023 −$4.86M
Current Liabilities FY 2025 · Dec 31, 2025 $11.01M
Current Liabilities FY 2025 · Dec 31, 2024 $8.98M
Total Liabilities FY 2025 · Dec 31, 2025 $11.01M
Total Liabilities FY 2025 · Dec 31, 2024 $9.6M
Current Assets FY 2025 · Dec 31, 2025 $307K
Current Assets FY 2025 · Dec 31, 2024 $385K
Total Assets FY 2025 · Dec 31, 2025 $1.02M
Total Assets FY 2025 · Dec 31, 2024 $1.83M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.11
Eps Diluted FY 2025 · Dec 31, 2024 −$2.31
Eps Basic FY 2025 · Dec 31, 2025 −$1.11
Eps Basic FY 2025 · Dec 31, 2024 −$2.31
Sga Expense FY 2025 · Dec 31, 2025 $5.78M
Sga Expense FY 2025 · Dec 31, 2024 $7.04M
Rd Expense FY 2025 · Dec 31, 2025 $4.18M
Rd Expense FY 2025 · Dec 31, 2024 $4.65M
Net Income FY 2025 · Dec 31, 2025 −$10.31M
Net Income FY 2025 · Dec 31, 2024 −$11.62M
Operating Income FY 2025 · Dec 31, 2025 −$9.95M
Operating Income FY 2025 · Dec 31, 2024 −$11.69M